Skip to main content
Journal cover image

Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?

Publication ,  Journal Article
Ba-Ssalamah, A; Bastati, N; Wibmer, A; Fragner, R; Hodge, JC; Trauner, M; Herold, CJ; Bashir, MR; Van Beers, BE
Published in: J Magn Reson Imaging
March 2017

UNLABELLED: MRI has emerged as the most comprehensive noninvasive diagnostic tool for focal liver lesions and diffuse hepatobiliary disorders. The introduction of hepatobiliary contrast agents, most notably gadoxetic acid (GA), has expanded the role of MRI, particularly in the functional imaging of chronic liver diseases, such as nonalcoholic fatty liver disease (NAFLD). GA-enhanced MRI (GA-MRI) may help to distinguish between the two subgroups of NAFLD, simple steatosis and nonalcoholic steatohepatitis. Furthermore, GA-MRI can be used to stage fibrosis and cirrhosis, predict liver transplant graft survival, and preoperatively estimate the risk of liver failure should major resection be undertaken. The amount of GA uptake can be estimated, using static images, by the relative liver enhancement, hepatic uptake index, and relaxometry of T1-mapping during the hepatobiliary phase. On the contrary, the hepatic extraction fraction and liver perfusion can be measured on dynamic imaging. Importantly, there is currently no clear consensus as to which of these MR-derived parameters is the most suitable for assessing liver dysfunction. This review article aims to describe the current role of GA-enhanced MRI in quantifying liver function, primarily in diffuse hepatobiliary disorders. LEVEL OF EVIDENCE: 3 J. Magn. Reson. Imaging 2017;45:646-659.

Duke Scholars

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

March 2017

Volume

45

Issue

3

Start / End Page

646 / 659

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Nuclear Medicine & Medical Imaging
  • Models, Biological
  • Metabolic Clearance Rate
  • Liver Function Tests
  • Liver Diseases
  • Liver
  • Image Interpretation, Computer-Assisted
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ba-Ssalamah, A., Bastati, N., Wibmer, A., Fragner, R., Hodge, J. C., Trauner, M., … Van Beers, B. E. (2017). Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging, 45(3), 646–659. https://doi.org/10.1002/jmri.25518
Ba-Ssalamah, Ahmed, Nina Bastati, Andreas Wibmer, Romana Fragner, Jacqueline C. Hodge, Michael Trauner, Christian J. Herold, Mustafa R. Bashir, and Bernard E. Van Beers. “Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?J Magn Reson Imaging 45, no. 3 (March 2017): 646–59. https://doi.org/10.1002/jmri.25518.
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017 Mar;45(3):646–59.
Ba-Ssalamah, Ahmed, et al. “Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?J Magn Reson Imaging, vol. 45, no. 3, Mar. 2017, pp. 646–59. Pubmed, doi:10.1002/jmri.25518.
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017 Mar;45(3):646–659.
Journal cover image

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

March 2017

Volume

45

Issue

3

Start / End Page

646 / 659

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Nuclear Medicine & Medical Imaging
  • Models, Biological
  • Metabolic Clearance Rate
  • Liver Function Tests
  • Liver Diseases
  • Liver
  • Image Interpretation, Computer-Assisted